FDAnews Drug Daily Bulletin

Anthera Buys Liprotamase from Lilly, Plans Phase III Trial

July 17, 2014
Eli Lilly has sold liprotamase to Anthera Pharmaceuticals, three years after the FDA halted development of the investigational pancreatic enzyme replacement therapy (PERT) through a complete response letter that followed an advisory committee recommendation against approval of the compound. The price was not disclosed.